Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

2.

Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y, Plitman E, Chung JK, Remington G, Graff-Guerrero A.

Psychopharmacology (Berl). 2016 Oct;233(21-22):3803-3813.

PMID:
27557949
3.

Antipsychotics and amotivation.

Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G.

Neuropsychopharmacology. 2015 May;40(6):1539-48. doi: 10.1038/npp.2015.3.

4.

Antipsychotic treatments; focus on lurasidone.

Sumiyoshi T.

Front Pharmacol. 2013 Aug 26;4:102. doi: 10.3389/fphar.2013.00102.

5.

Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease.

Weickert TW, Mattay VS, Das S, Bigelow LB, Apud JA, Egan MF, Weinberger DR, Goldberg TE.

Schizophr Res. 2013 Sep;149(1-3):162-6. doi: 10.1016/j.schres.2013.06.028.

6.

GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia.

Volk DW, Lewis DA.

Curr Neuropharmacol. 2005 Jan;3(1):45-62.

7.

Risperidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Review.

8.

Clozapine versus other atypical antipsychotics for schizophrenia.

Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006633. doi: 10.1002/14651858.CD006633.pub2. Review.

9.

The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia.

Selva-Vera G, Balanzá-Martínez V, Salazar-Fraile J, Sánchez-Moreno J, Martinez-Aran A, Correa P, Vieta E, Tabarés-Seisdedos R.

BMC Psychiatry. 2010 Jun 15;10:47. doi: 10.1186/1471-244X-10-47.

10.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

11.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006625. doi: 10.1002/14651858.CD006625.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;11:CD006625.

12.

Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.

Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD.

Neuropsychopharmacology. 2010 Apr;35(5):1053-62. doi: 10.1038/npp.2009.211. Review.

13.
14.

Impaired top-down control of visual search in schizophrenia.

Gold JM, Fuller RL, Robinson BM, Braun EL, Luck SJ.

Schizophr Res. 2007 Aug;94(1-3):148-55.

15.
Items per page

Supplemental Content

Support Center